Author Archives:
2011 – Caroline Budner
Since the founding of Matt’s Promise and our very first event in 2006 Caroline has contributed tirelessly to our work and cause. She is always there to help handle the details. Her efforts support our annual event, help us to keep the day to day operations flowing smoothly and she volunteers her time and organizational skills to all of our events and activities. Caroline says,
Charley’s Fund and Duchenne Muscular Dystrophy
The cornerstone project of Matt’s Promise is research for the treatment and cure of Duchenne Muscular Dystrophy (DMD). While receiving treatment for his own terminal disease, Matt learned that the then three-year-old son of his childhood best friend was diagnosed with this dreadful and devastating disease. The news hit Matt hard, and he was determined to do all that he could to help Charley and other young people receive the best medical care and emotional support available and to fund research to find a cure.
Pilot Trials
“There is not one FDA approved drug I can offer”
Those are the words Dr. Brian Tseng must utter when families come to his clinic at Massachusetts General hospital seeking a treatment for thier children with Duchenne Muscular Dystrophy (DMD). This disease is the number one genetic killer of children worldwide. For the first time ever in the history of this notorious disease, groundbreaking new therapies are being developed.
Inspiring Research
Matt’s Promise has been proud to support the research of Dr. Melinda Merchant, which explores the development of new targeted therapies against sarcomas such as Ewing’s sarcoma, synovial sarcoma, and desmoplastic small-round-cell tumor. Funds raised during the Matt’s Promise Memory Run went to furthering
News From Charley’s Fund
For the past seven years, with your help we have been funding medical research in the hope of finding a treatment that could save Charley’s life and the lives of thousands of children like him who have been struck by Duchenne muscular dystrophy. Now, we have arrived at a crucial turning point. Human clinical trials are finally underway. Additional trials will start in 2012 and 2013 as long as we continue to fund the development of these promising medications.